Fortrea Holdings Inc.

NASDAQ:FTRE

Biotechnology

Healthcare
$20.50 -0.46%

-$0.07 today

Market cap
$1.94B
Beta
2.11
P/E (TTM)
-3.1
EPS (TTM)
-$4.90
52W Low $4.36High $18.67

Volume 1.59M

Average 1.31M

FTRE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fortrea Holdings Inc.NASDAQ: FTRE

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How FTRE compares with its peers on the latest reported figures

  • FTRE's LTM Jun 2026 research & development of $0 is the 2nd highest of the 3 companies compared; the peer median is $21.4M.
  • Research & development amounts to 0.0% of revenue for FTRE, versus a peer median of 5.1%.
FTRE Competitors Peer median
Research & Development for FTRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERTCertara, Inc.LTM Mar 2026$42.8M +20.1%+13.3%10.2%
FTREFortrea Holdings Inc.LTM Jun 2026$0 ——0.0%
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding FTRE) $21.4M+20.1%+13.3%5.1%

Competitors are the stored peer set for FTRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.06B2.84B2.84B2.7B2.72B
Cost of Revenue2.45B2.11B2.25B2.16B2.3B
Gross Profit604.4M724.4M590.6M534.2M425.8M
Gross Margin19.8%25.5%20.8%19.8%15.6%
Research & Development00000
Selling, General & Admin303.1M416.1M448.1M560.7M456.4M
Operating Expenses490.1M537.3M558.6M696.1M456.4M
Depreciation & Amortization166.3M93.6M98M86.9M78M
EBITDA302.9M280.8M137.2M(64.3M)(813.6M)
EBITDA Margin9.9%9.9%4.8%-2.4%-29.9%
Operating Income114.3M187.1M32M(161.9M)(30.6M)
Operating Margin3.7%6.6%1.1%-6.0%-1.1%
Interest Income00000
Interest Expense200K200K69.8M123.8M91.4M
Other Income / Expenses22.1M(100K)(62.5M)(113.1M)(952.4M)
Income Before Tax136.4M187M(30.5M)(275M)(983M)
Pre-Tax Margin4.5%6.6%-1.1%-10.2%-36.1%
Income Tax Expense38.4M41.1M1.2M(3.5M)3.2M
Net Income98M186.2M(25.2M)(328.5M)(986.2M)
Net Margin3.2%6.6%-0.9%-12.2%-36.2%
EPS (Basic)1.112.11(0.04)(3.67)(10.81)
EPS (Diluted)1.112.11(0.04)(3.67)(10.81)
Weighted Avg Shares88.4M88.4M88.8M89.5M91.2M
Weighted Avg Shares (Diluted)88.4M88.4M88.8M89.5M91.2M

Fortrea Holdings Inc.

NASDAQ:FTRE

Intrinsic Alpha fair value

Locked

Current Price

$20.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.